Prucalopride  ||| S:0 E:13 ||| NNP
for  ||| S:13 E:17 ||| IN
the  ||| S:17 E:21 ||| DT
treatment  ||| S:21 E:31 ||| NN
of  ||| S:31 E:34 ||| IN
women  ||| S:34 E:40 ||| NNS
with  ||| S:40 E:45 ||| IN
chronic  ||| S:45 E:53 ||| JJ
constipation  ||| S:53 E:66 ||| NN
in  ||| S:66 E:69 ||| IN
whom  ||| S:69 E:74 ||| WP
standard  ||| S:74 E:83 ||| JJ
laxative  ||| S:83 E:92 ||| NN
regimens  ||| S:92 E:101 ||| NNS
have  ||| S:101 E:106 ||| VBP
failed  ||| S:106 E:113 ||| VBN
to  ||| S:113 E:116 ||| TO
provide  ||| S:116 E:124 ||| VB
adequate  ||| S:124 E:133 ||| JJ
relief  ||| S:133 E:140 ||| NN
This  ||| S:140 E:145 ||| DT
paper  ||| S:145 E:151 ||| NN
presents  ||| S:151 E:160 ||| VBZ
a  ||| S:160 E:162 ||| DT
summary  ||| S:162 E:170 ||| NN
of  ||| S:170 E:173 ||| IN
the  ||| S:173 E:177 ||| DT
evidence  ||| S:177 E:186 ||| NN
review  ||| S:186 E:193 ||| NN
group  ||| S:193 E:199 ||| NN
( ||| S:199 E:200 ||| -LRB-
ERG ||| S:200 E:203 ||| NNP
)  ||| S:203 E:205 ||| -RRB-
report  ||| S:205 E:212 ||| NN
into  ||| S:212 E:217 ||| IN
the  ||| S:217 E:221 ||| DT
clinical  ||| S:221 E:230 ||| JJ
effectiveness  ||| S:230 E:244 ||| NN
and  ||| S:244 E:248 ||| CC
cost-effectiveness  ||| S:248 E:267 ||| JJ
of  ||| S:267 E:270 ||| IN
prucalopride  ||| S:270 E:283 ||| NN
for  ||| S:283 E:287 ||| IN
the  ||| S:287 E:291 ||| DT
treatment  ||| S:291 E:301 ||| NN
of  ||| S:301 E:304 ||| IN
women  ||| S:304 E:310 ||| NNS
with  ||| S:310 E:315 ||| IN
chronic  ||| S:315 E:323 ||| JJ
constipation  ||| S:323 E:336 ||| NN
in  ||| S:336 E:339 ||| IN
whom  ||| S:339 E:344 ||| WP
standard  ||| S:344 E:353 ||| JJ
laxative  ||| S:353 E:362 ||| NN
regimens  ||| S:362 E:371 ||| NNS
have  ||| S:371 E:376 ||| VBP
failed  ||| S:376 E:383 ||| VBN
to  ||| S:383 E:386 ||| TO
provide  ||| S:386 E:394 ||| VB
adequate  ||| S:394 E:403 ||| JJ
relief ||| S:403 E:409 ||| NN
.  ||| S:409 E:411 ||| .
The  ||| S:411 E:415 ||| DT
ERG  ||| S:415 E:419 ||| NNP
report  ||| S:419 E:426 ||| NN
is  ||| S:426 E:429 ||| VBZ
based  ||| S:429 E:435 ||| VBN
on  ||| S:435 E:438 ||| IN
the  ||| S:438 E:442 ||| DT
manufacturer ||| S:442 E:454 ||| NN
's  ||| S:454 E:457 ||| POS
submission  ||| S:457 E:468 ||| NN
( ||| S:468 E:469 ||| -LRB-
MS ||| S:469 E:471 ||| NNP
)  ||| S:471 E:473 ||| -RRB-
to  ||| S:473 E:476 ||| TO
the  ||| S:476 E:480 ||| DT
National  ||| S:480 E:489 ||| NNP
Institute  ||| S:489 E:499 ||| NNP
for  ||| S:499 E:503 ||| IN
Health  ||| S:503 E:510 ||| NNP
and  ||| S:510 E:514 ||| CC
Clinical  ||| S:514 E:523 ||| NNP
Excellence  ||| S:523 E:534 ||| NNP
as  ||| S:534 E:537 ||| IN
part  ||| S:537 E:542 ||| NN
of  ||| S:542 E:545 ||| IN
the  ||| S:545 E:549 ||| DT
single  ||| S:549 E:556 ||| JJ
technology  ||| S:556 E:567 ||| NN
appraisal  ||| S:567 E:577 ||| NN
process ||| S:577 E:584 ||| NN
.  ||| S:584 E:586 ||| .
In  ||| S:586 E:589 ||| IN
the  ||| S:589 E:593 ||| DT
submission ||| S:593 E:603 ||| NN
,  ||| S:603 E:605 ||| ,
quality-of-life  ||| S:605 E:621 ||| JJ
data  ||| S:621 E:626 ||| NNS
[ ||| S:626 E:627 ||| -LRB-
Patient  ||| S:627 E:635 ||| NNP
Assessment  ||| S:635 E:646 ||| NNP
of  ||| S:646 E:649 ||| IN
Constipation  ||| S:649 E:662 ||| NNP
Quality  ||| S:662 E:670 ||| NNP
of  ||| S:670 E:673 ||| IN
Life  ||| S:673 E:678 ||| NNP
( ||| S:678 E:679 ||| -LRB-
PAC-QOL ||| S:679 E:686 ||| NNP
)  ||| S:686 E:688 ||| -RRB-
and  ||| S:688 E:692 ||| CC
Patient  ||| S:692 E:700 ||| NNP
Assessment  ||| S:700 E:711 ||| NNP
of  ||| S:711 E:714 ||| IN
Constipation  ||| S:714 E:727 ||| NNP
Symptoms  ||| S:727 E:736 ||| NNP
( ||| S:736 E:737 ||| -LRB-
PAC-SYM ||| S:737 E:744 ||| NNP
)  ||| S:744 E:746 ||| -RRB-
questionnaires ||| S:746 E:760 ||| NN
]  ||| S:760 E:762 ||| -RRB-
from  ||| S:762 E:767 ||| IN
trials  ||| S:767 E:774 ||| NNS
of  ||| S:774 E:777 ||| IN
prucalopride  ||| S:777 E:790 ||| NN
were  ||| S:790 E:795 ||| VBD
extrapolated  ||| S:795 E:808 ||| VBN
to  ||| S:808 E:811 ||| TO
EQ-5D  ||| S:811 E:817 ||| CD
( ||| S:817 E:818 ||| -LRB-
European  ||| S:818 E:827 ||| NNP
Quality  ||| S:827 E:835 ||| NNP
of  ||| S:835 E:838 ||| IN
Life-5  ||| S:838 E:845 ||| NNP
Dimensions ||| S:845 E:855 ||| NNP
)  ||| S:855 E:857 ||| -RRB-
data  ||| S:857 E:862 ||| NNS
and  ||| S:862 E:866 ||| CC
used  ||| S:866 E:871 ||| VBN
to  ||| S:871 E:874 ||| TO
inform  ||| S:874 E:881 ||| VB
effectiveness  ||| S:881 E:895 ||| NN
in  ||| S:895 E:898 ||| IN
an  ||| S:898 E:901 ||| DT
economic  ||| S:901 E:910 ||| JJ
model ||| S:910 E:915 ||| NN
.  ||| S:915 E:917 ||| .
Response  ||| S:917 E:926 ||| NN
rates  ||| S:926 E:932 ||| NNS
to  ||| S:932 E:935 ||| TO
prucalopride  ||| S:935 E:948 ||| NNS
were  ||| S:948 E:953 ||| VBD
derived  ||| S:953 E:961 ||| VBN
from  ||| S:961 E:966 ||| IN
observed  ||| S:966 E:975 ||| JJ
response  ||| S:975 E:984 ||| NN
rates  ||| S:984 E:990 ||| NNS
in  ||| S:990 E:993 ||| IN
trials ||| S:993 E:999 ||| NNS
,  ||| S:999 E:1001 ||| ,
defined  ||| S:1001 E:1009 ||| VBN
as  ||| S:1009 E:1012 ||| IN
the  ||| S:1012 E:1016 ||| DT
proportion  ||| S:1016 E:1027 ||| NN
of  ||| S:1027 E:1030 ||| IN
patients  ||| S:1030 E:1039 ||| NNS
achieving  ||| S:1039 E:1049 ||| VBG
an  ||| S:1049 E:1052 ||| DT
average  ||| S:1052 E:1060 ||| NN
of  ||| S:1060 E:1063 ||| IN
three  ||| S:1063 E:1069 ||| CD
or  ||| S:1069 E:1072 ||| CC
more  ||| S:1072 E:1077 ||| RBR
spontaneous  ||| S:1077 E:1089 ||| JJ
complete  ||| S:1089 E:1098 ||| JJ
bowel  ||| S:1098 E:1104 ||| NN
movements  ||| S:1104 E:1114 ||| NNS
over  ||| S:1114 E:1119 ||| IN
the  ||| S:1119 E:1123 ||| DT
4-  ||| S:1123 E:1126 ||| NNP
or  ||| S:1126 E:1129 ||| CC
12-week  ||| S:1129 E:1137 ||| CD
trial  ||| S:1137 E:1143 ||| NN
periods ||| S:1143 E:1150 ||| NNS
.  ||| S:1150 E:1152 ||| .
Adult  ||| S:1152 E:1158 ||| NNP
( ||| S:1158 E:1159 ||| -LRB-
18-64  ||| S:1159 E:1165 ||| CD
years ||| S:1165 E:1170 ||| NNS
)  ||| S:1170 E:1172 ||| -RRB-
and  ||| S:1172 E:1176 ||| CC
elderly  ||| S:1176 E:1184 ||| JJ
( ||| S:1184 E:1185 ||| -LRB-
â‰¥  ||| S:1185 E:1187 ||| CD
65  ||| S:1187 E:1190 ||| CD
years ||| S:1190 E:1195 ||| NNS
)  ||| S:1195 E:1197 ||| -RRB-
patients  ||| S:1197 E:1206 ||| NNS
were  ||| S:1206 E:1211 ||| VBD
considered  ||| S:1211 E:1222 ||| VBN
separately  ||| S:1222 E:1233 ||| RB
in  ||| S:1233 E:1236 ||| IN
the  ||| S:1236 E:1240 ||| DT
model ||| S:1240 E:1245 ||| NN
.  ||| S:1245 E:1247 ||| .
Cost-effectiveness  ||| S:1247 E:1266 ||| NNP
was  ||| S:1266 E:1270 ||| VBD
determined  ||| S:1270 E:1281 ||| VBN
from  ||| S:1281 E:1286 ||| IN
estimated  ||| S:1286 E:1296 ||| JJ
improvements  ||| S:1296 E:1309 ||| NNS
in  ||| S:1309 E:1312 ||| IN
EQ-5D  ||| S:1312 E:1318 ||| NNP
and  ||| S:1318 E:1322 ||| CC
anticipated  ||| S:1322 E:1334 ||| JJ
response  ||| S:1334 E:1343 ||| NN
rates ||| S:1343 E:1348 ||| NNS
,  ||| S:1348 E:1350 ||| ,
adjusted  ||| S:1350 E:1359 ||| VBN
for  ||| S:1359 E:1363 ||| IN
baseline  ||| S:1363 E:1372 ||| JJ
severity  ||| S:1372 E:1381 ||| NN
of  ||| S:1381 E:1384 ||| IN
chronic  ||| S:1384 E:1392 ||| JJ
constipation ||| S:1392 E:1404 ||| NN
.  ||| S:1404 E:1406 ||| .
The  ||| S:1406 E:1410 ||| DT
ERG  ||| S:1410 E:1414 ||| NNP
considered  ||| S:1414 E:1425 ||| VBD
that  ||| S:1425 E:1430 ||| IN
the  ||| S:1430 E:1434 ||| DT
patients  ||| S:1434 E:1443 ||| NNS
participating  ||| S:1443 E:1457 ||| VBG
in  ||| S:1457 E:1460 ||| IN
these  ||| S:1460 E:1466 ||| DT
trials  ||| S:1466 E:1473 ||| NNS
were  ||| S:1473 E:1478 ||| VBD
not  ||| S:1478 E:1482 ||| RB
representative  ||| S:1482 E:1497 ||| JJ
of  ||| S:1497 E:1500 ||| IN
those  ||| S:1500 E:1506 ||| DT
in  ||| S:1506 E:1509 ||| IN
the  ||| S:1509 E:1513 ||| DT
licensed  ||| S:1513 E:1522 ||| JJ
indication ||| S:1522 E:1532 ||| NN
.  ||| S:1532 E:1534 ||| .
They  ||| S:1534 E:1539 ||| PRP
were  ||| S:1539 E:1544 ||| VBD
not  ||| S:1544 E:1548 ||| RB
all  ||| S:1548 E:1552 ||| DT
refractory  ||| S:1552 E:1563 ||| JJ
to  ||| S:1563 E:1566 ||| TO
laxatives ||| S:1566 E:1575 ||| VB
,  ||| S:1575 E:1577 ||| ,
and  ||| S:1577 E:1581 ||| CC
baseline  ||| S:1581 E:1590 ||| CD
EQ-5D  ||| S:1590 E:1596 ||| CD
scores  ||| S:1596 E:1603 ||| NNS
showed  ||| S:1603 E:1610 ||| VBD
a  ||| S:1610 E:1612 ||| DT
large  ||| S:1612 E:1618 ||| JJ
spread  ||| S:1618 E:1625 ||| NN
in  ||| S:1625 E:1628 ||| IN
quality  ||| S:1628 E:1636 ||| NN
of  ||| S:1636 E:1639 ||| IN
life ||| S:1639 E:1643 ||| NN
,  ||| S:1643 E:1645 ||| ,
with  ||| S:1645 E:1650 ||| IN
many  ||| S:1650 E:1655 ||| JJ
patients  ||| S:1655 E:1664 ||| NNS
experiencing  ||| S:1664 E:1677 ||| VBG
little  ||| S:1677 E:1684 ||| JJ
baseline  ||| S:1684 E:1693 ||| NN
dissatisfaction ||| S:1693 E:1708 ||| NN
.  ||| S:1708 E:1710 ||| .
The  ||| S:1710 E:1714 ||| DT
mapping  ||| S:1714 E:1722 ||| NN
of  ||| S:1722 E:1725 ||| IN
quality-of-life  ||| S:1725 E:1741 ||| JJ
data  ||| S:1741 E:1746 ||| NNS
from  ||| S:1746 E:1751 ||| IN
trials  ||| S:1751 E:1758 ||| NNS
( ||| S:1758 E:1759 ||| -LRB-
PAC-QOL  ||| S:1759 E:1767 ||| NNP
and  ||| S:1767 E:1771 ||| CC
PAC-SYM  ||| S:1771 E:1779 ||| JJ
data ||| S:1779 E:1783 ||| NNS
)  ||| S:1783 E:1785 ||| -RRB-
to  ||| S:1785 E:1788 ||| TO
EQ-5D  ||| S:1788 E:1794 ||| NNP
was  ||| S:1794 E:1798 ||| VBD
unclear  ||| S:1798 E:1806 ||| JJ
and  ||| S:1806 E:1810 ||| CC
invalidated ||| S:1810 E:1821 ||| NN
.  ||| S:1821 E:1823 ||| .
The  ||| S:1823 E:1827 ||| DT
assumption  ||| S:1827 E:1838 ||| NN
of  ||| S:1838 E:1841 ||| IN
the  ||| S:1841 E:1845 ||| DT
long-term  ||| S:1845 E:1855 ||| JJ
effectiveness  ||| S:1855 E:1869 ||| NN
and  ||| S:1869 E:1873 ||| CC
safety  ||| S:1873 E:1880 ||| NN
of  ||| S:1880 E:1883 ||| IN
prucalopride  ||| S:1883 E:1896 ||| VBG
to  ||| S:1896 E:1899 ||| TO
1  ||| S:1899 E:1901 ||| CD
year  ||| S:1901 E:1906 ||| NN
was  ||| S:1906 E:1910 ||| VBD
considered  ||| S:1910 E:1921 ||| VBN
unjustified ||| S:1921 E:1932 ||| NN
.  ||| S:1932 E:1934 ||| .
There  ||| S:1934 E:1940 ||| EX
was  ||| S:1940 E:1944 ||| VBD
no  ||| S:1944 E:1947 ||| DT
justification  ||| S:1947 E:1961 ||| NN
or  ||| S:1961 E:1964 ||| CC
sources  ||| S:1964 E:1972 ||| NNS
given  ||| S:1972 E:1978 ||| VBN
for  ||| S:1978 E:1982 ||| IN
coefficients  ||| S:1982 E:1995 ||| VBG
used  ||| S:1995 E:2000 ||| VBN
to  ||| S:2000 E:2003 ||| TO
predict  ||| S:2003 E:2011 ||| VB
effectiveness  ||| S:2011 E:2025 ||| NN
in  ||| S:2025 E:2028 ||| IN
the  ||| S:2028 E:2032 ||| DT
economic  ||| S:2032 E:2041 ||| JJ
model ||| S:2041 E:2046 ||| NN
,  ||| S:2046 E:2048 ||| ,
and  ||| S:2048 E:2052 ||| CC
no  ||| S:2052 E:2055 ||| DT
costs  ||| S:2055 E:2061 ||| NNS
other  ||| S:2061 E:2067 ||| JJ
than  ||| S:2067 E:2072 ||| IN
the  ||| S:2072 E:2076 ||| DT
cost  ||| S:2076 E:2081 ||| NN
of  ||| S:2081 E:2084 ||| IN
prucalopride  ||| S:2084 E:2097 ||| NN
were  ||| S:2097 E:2102 ||| VBD
incorporated  ||| S:2102 E:2115 ||| VBN
into  ||| S:2115 E:2120 ||| IN
the  ||| S:2120 E:2124 ||| DT
model ||| S:2124 E:2129 ||| NN
.  ||| S:2129 E:2131 ||| .
Owing  ||| S:2131 E:2137 ||| VBG
to  ||| S:2137 E:2140 ||| TO
the  ||| S:2140 E:2144 ||| DT
many  ||| S:2144 E:2149 ||| JJ
areas  ||| S:2149 E:2155 ||| NNS
of  ||| S:2155 E:2158 ||| IN
uncertainty ||| S:2158 E:2169 ||| NN
,  ||| S:2169 E:2171 ||| ,
particularly  ||| S:2171 E:2184 ||| RB
the  ||| S:2184 E:2188 ||| DT
effectiveness  ||| S:2188 E:2202 ||| NN
of  ||| S:2202 E:2205 ||| IN
prucalopride  ||| S:2205 E:2218 ||| NN
in  ||| S:2218 E:2221 ||| IN
the  ||| S:2221 E:2225 ||| DT
licensed  ||| S:2225 E:2234 ||| JJ
patient  ||| S:2234 E:2242 ||| NN
group  ||| S:2242 E:2248 ||| NN
and  ||| S:2248 E:2252 ||| CC
its  ||| S:2252 E:2256 ||| PRP$
long-term  ||| S:2256 E:2266 ||| JJ
effectiveness  ||| S:2266 E:2280 ||| NN
and  ||| S:2280 E:2284 ||| CC
safety ||| S:2284 E:2290 ||| NN
,  ||| S:2290 E:2292 ||| ,
it  ||| S:2292 E:2295 ||| PRP
was  ||| S:2295 E:2299 ||| VBD
considered  ||| S:2299 E:2310 ||| VBN
that  ||| S:2310 E:2315 ||| IN
the  ||| S:2315 E:2319 ||| DT
MS  ||| S:2319 E:2322 ||| NNP
provided  ||| S:2322 E:2331 ||| VBD
no  ||| S:2331 E:2334 ||| DT
evidence  ||| S:2334 E:2343 ||| NN
for  ||| S:2343 E:2347 ||| IN
whether  ||| S:2347 E:2355 ||| IN
prucalopride  ||| S:2355 E:2368 ||| NN
is  ||| S:2368 E:2371 ||| VBZ
effective  ||| S:2371 E:2381 ||| JJ
or  ||| S:2381 E:2384 ||| CC
not  ||| S:2384 E:2388 ||| RB
in  ||| S:2388 E:2391 ||| IN
women  ||| S:2391 E:2397 ||| NNS
with  ||| S:2397 E:2402 ||| IN
laxative-refractory  ||| S:2402 E:2422 ||| JJ
chronic  ||| S:2422 E:2430 ||| JJ
constipation ||| S:2430 E:2442 ||| NN
.  ||| S:2442 E:2444 ||| .
Further  ||| S:2444 E:2452 ||| RBR
subgroup  ||| S:2452 E:2461 ||| JJ
analysis  ||| S:2461 E:2470 ||| NN
of  ||| S:2470 E:2473 ||| IN
the  ||| S:2473 E:2477 ||| DT
actual  ||| S:2477 E:2484 ||| JJ
patient  ||| S:2484 E:2492 ||| NN
group  ||| S:2492 E:2498 ||| NN
of  ||| S:2498 E:2501 ||| IN
interest  ||| S:2501 E:2510 ||| NN
may  ||| S:2510 E:2514 ||| MD
have  ||| S:2514 E:2519 ||| VB
better  ||| S:2519 E:2526 ||| RBR
guided  ||| S:2526 E:2533 ||| JJ
decision-making ||| S:2533 E:2548 ||| NN
.  ||| S:2548 E:2550 ||| .
However ||| S:2550 E:2557 ||| RB
,  ||| S:2557 E:2559 ||| ,
long-term  ||| S:2559 E:2569 ||| JJ
efficacy  ||| S:2569 E:2578 ||| JJ
data ||| S:2578 E:2582 ||| NNS
,  ||| S:2582 E:2584 ||| ,
with  ||| S:2584 E:2589 ||| IN
validated  ||| S:2589 E:2599 ||| JJ
estimates  ||| S:2599 E:2609 ||| NNS
of  ||| S:2609 E:2612 ||| IN
quality  ||| S:2612 E:2620 ||| NN
of  ||| S:2620 E:2623 ||| IN
life  ||| S:2623 E:2628 ||| NN
incorporated  ||| S:2628 E:2641 ||| VBN
in  ||| S:2641 E:2644 ||| IN
a  ||| S:2644 E:2646 ||| DT
well-founded  ||| S:2646 E:2659 ||| JJ
model ||| S:2659 E:2664 ||| NN
,  ||| S:2664 E:2666 ||| ,
would  ||| S:2666 E:2672 ||| MD
be  ||| S:2672 E:2675 ||| VB
important  ||| S:2675 E:2685 ||| JJ
for  ||| S:2685 E:2689 ||| IN
an  ||| S:2689 E:2692 ||| DT
evidence-based  ||| S:2692 E:2707 ||| JJ
judgement  ||| S:2707 E:2717 ||| NN
to  ||| S:2717 E:2720 ||| TO
be  ||| S:2720 E:2723 ||| VB
made ||| S:2723 E:2727 ||| VBN
.  ||| S:2727 E:2729 ||| .
